{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:10:08Z","timestamp":1793427008848,"version":"4.5.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1097\/inf.0000000000000793","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T18:23:27Z","timestamp":1435083807000},"page":"983-991","source":"Crossref","is-referenced-by-count":113,"title":["An Overview of Quadrivalent Human Papillomavirus Vaccine Safety"],"prefix":"10.1097","volume":"34","author":[{"given":"Michelle","family":"Vichnin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan L.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne K.","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Sings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred J.","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lievano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Velicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosybel","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210202","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Females United to Unilaterally Reduce EndoEctocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-17-20210202","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"R4-17-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R5-17-20210202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-17-20210202","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"R9-17-20210202","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/INF.0b013e3181b77906","article-title":"Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine.","volume":"29","author":"Block","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R10-17-20210202","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"R11-17-20210202","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2010.04.070","article-title":"A summary of the post-licensure surveillance initiatives for GARDASILSILGARD.","volume":"28","author":"Bonanni","year":"2010","journal-title":"Vaccine"},{"key":"R13-17-20210202","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"R16-17-20210202","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"BMJ"},{"key":"R17-17-20210202","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.2014.2198","article-title":"Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism.","volume":"312","author":"Scheller","year":"2014","journal-title":"JAMA"},{"key":"R18-17-20210202","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"key":"R19-17-20210202","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/jamaneurol.2014.2633","article-title":"Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases.","volume":"71","author":"Langer-Gould","year":"2014","journal-title":"JAMA Neurol"},{"key":"R20-17-20210202","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archpediatrics.2012.1451","article-title":"Safety of quadrivalent human papillomavirus vaccine administered routinely to females.","volume":"166","author":"Klein","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R21-17-20210202","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"R22-17-20210202","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"PGRx-AID Study Group. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"key":"R25-17-20210202","doi-asserted-by":"crossref","first-page":"e83431","DOI":"10.1371\/journal.pone.0083431","article-title":"Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women.","volume":"8","author":"Luna","year":"2013","journal-title":"PLoS One"},{"key":"R27-17-20210202","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","article-title":"The role of the vaccine adverse event reporting system (VAERS) in monitoring vaccine safety.","volume":"33","author":"Iskander","year":"2004","journal-title":"Pediatr Ann"},{"key":"R28-17-20210202","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)-United States, 1991-2001.","volume":"52","author":"Zhou","year":"2003","journal-title":"MMWR Surveill Summ"},{"key":"R29-17-20210202","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2010.02.019","article-title":"Post-licensure monitoring of HPV vaccine in the United States.","volume":"28","author":"Markowitz","year":"2010","journal-title":"Vaccine"},{"key":"R30-17-20210202","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"R31-17-20210202","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.vaccine.2014.11.047","article-title":"Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.","volume":"33","author":"Moro","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"R32-17-20210202","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.ypmed.2011.08.015","article-title":"Adolescent and young adult HPV vaccination in Australia: achievements and challenges.","volume":"53","author":"Garland","year":"2011","journal-title":"Prev Med"},{"key":"R33-17-20210202","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.vaccine.2013.11.075","article-title":"Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey.","volume":"32","author":"Brotherton","year":"2014","journal-title":"Vaccine"},{"key":"R36-17-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5694\/j.1326-5377.2011.tb04138.x","article-title":"Syncope and seizures following human papillomavirus vaccination: a retrospective case series.","volume":"194","author":"Crawford","year":"2011","journal-title":"Med J Aust"},{"key":"R37-17-20210202","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1474-4422(06)70350-7","article-title":"Seizure versus syncope.","volume":"5","author":"McKeon","year":"2006","journal-title":"Lancet Neurol"},{"key":"R38-17-20210202","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"New South Wales Health HPV Adverse Events Panel. Anaphylaxis following quadrivalent human papillomavirus vaccination.","volume":"179","author":"Brotherton","year":"2008","journal-title":"CMAJ"},{"key":"R39-17-20210202","doi-asserted-by":"crossref","first-page":"a2642","DOI":"10.1136\/bmj.a2642","article-title":"Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.","volume":"337","author":"Kang","year":"2008","journal-title":"BMJ"},{"key":"R40-17-20210202","first-page":"620","article-title":"Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States.","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R41-17-20210202","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Quadrivalent Human Papillomavirus Vaccine Phase III Investigators. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6111618 vaccine: a combined analysis of five randomized controlled trials.","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R43-17-20210202","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R44-17-20210202","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181de8d26","article-title":"IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.","volume":"55","author":"Levin","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R45-17-20210202","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R46-17-20210202","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10067-013-2266-7","article-title":"Human papillomavirus vaccine and systemic lupus erythematosus.","volume":"32","author":"Gatto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R48-17-20210202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review.","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf"},{"key":"R51-17-20210202","doi-asserted-by":"crossref","first-page":"614","DOI":"10.5694\/mja13.10272","article-title":"Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.","volume":"199","author":"Brotherton","year":"2013","journal-title":"Med J Aust"},{"key":"R52-17-20210202","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6111618 vaccine.","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R59-17-20210202","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","article-title":"Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions.","volume":"26","author":"Siegrist","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R60-17-20210202","doi-asserted-by":"crossref","first-page":"554","DOI":"10.5694\/mja12.11751","article-title":"Human papillomavirus vaccine in boys: background rates of potential adverse events.","volume":"198","author":"Clothier","year":"2013","journal-title":"Med J Aust"},{"issue":"RR-15","key":"R61-17-20210202","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"55","author":"Kroger","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"R63-17-20210202","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1542\/peds.2012-2384","article-title":"Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010.","volume":"131","author":"Darden","year":"2013","journal-title":"Pediatrics"},{"key":"R64-17-20210202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamapediatrics.2013.2752","article-title":"Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature.","volume":"168","author":"Holman","year":"2014","journal-title":"JAMA Pediatr"},{"key":"R67-17-20210202","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"R68-17-20210202","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program.","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J Infect Dis"},{"key":"R70-17-20210202","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"key":"R71-17-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2012.10.092","article-title":"Impact of human papillomavirus (HPV) vaccination on HPV 1618-related prevalence in precancerous cervical lesions.","volume":"31","author":"Powell","year":"2012","journal-title":"Vaccine"},{"key":"R72-17-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"R73-17-20210202","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"R74-17-20210202","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2334-13-140","article-title":"Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program.","volume":"13","author":"Ali","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R75-17-20210202","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/sextrans-2011-050234","article-title":"The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.","volume":"87","author":"Read","year":"2011","journal-title":"Sex Transm Infect"},{"key":"R76-17-20210202","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2105\/AJPH.2011.300465","article-title":"Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010.","volume":"102","author":"Bauer","year":"2012","journal-title":"Am J Public Health"},{"key":"R77-17-20210202","first-page":"17","article-title":"Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine.","volume":"20","author":"Nsouli-Maktabi","year":"2013","journal-title":"MSMR"},{"key":"R78-17-20210202","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/jis405","article-title":"Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.","volume":"206","author":"Leval","year":"2012","journal-title":"J Infect Dis"},{"key":"R79-17-20210202","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/OLQ.0b013e31827bd66b","article-title":"Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.","volume":"40","author":"Baandrup","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R80-17-20210202","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/OLQ.0b013e3182756efd","article-title":"Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study.","volume":"40","author":"Mikolajczyk","year":"2013","journal-title":"Sex Transm Dis"},{"key":"R81-17-20210202","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/cit436","article-title":"Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.","volume":"57","author":"Blomberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R82-17-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2334-14-87","article-title":"Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling.","volume":"14","author":"Delere","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R83-17-20210202","doi-asserted-by":"crossref","first-page":"djt460","DOI":"10.1093\/jnci\/djt460","article-title":"Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women.","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R84-17-20210202","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12325-015-0178-4","article-title":"Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.","volume":"32","author":"Mariani","year":"2015","journal-title":"Adv Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006454-201509000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:59:36Z","timestamp":1618279176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201509000-00017"}},"subtitle":["2006 to 2015"],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000793","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}